Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series

Despite the promising result with FLT3 inhibitors in AML, the emergence of resistance poses a significant challenge, leading to a shorter response duration and inferior survival. This is frequently driven by on-target or parallel prosurvival mutations. The emergence of BCR–ABL1 as a mechanism of pos...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Alotaibi, Ahmad S., Yilmaz, Musa, Loghavi, Sanam, DiNardo, Courtney, Borthakur, Gautam, Kadia, Tapan M., Thakral, Beenu, Pemmaraju, Naveen, Issa, Ghayas C., Konopleva, Marina, Short, Nicholas J., Patel, Keyur, Tang, Guilin, Ravandi, Farhad, Daver, Naval
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7606916/
https://ncbi.nlm.nih.gov/pubmed/33194747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.588876
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares